Objective To observe the clinical effects of ambroxol and bromhexine in adjuvant treatment of infants with acute bronchitis. Methods 98 cases of infants with acute bronchitis admitted to our hospital from September 2014 to June 2015 were selected as research objects, and divided into two groups, with 49 cases in each group. All cases received routine therapy;in addition, the observation group received ambroxol for intravenous drip, while the control group received bromhexine for intravenous drip. After 7 days of treatment, the clinical effects of two groups were compared, and the time for clinical symptoms improved and length of hospital stay were observed. Results The total effective rate of observation group was 97.96%, significantly higher than 79.59%of control group (P<0.05). The time for cough disappeared, time for pulmonary rales disappeared and length of hospital stay of observation group were significantly shorter than those of control group (P <0.05). No adverse reaction was found in both groups. Conclusions Ambroxol has better efficacy than bromhexine in adjuvant treatment of infants with acute bronchitis. It can relieve patients' symtoms, and has good tolerance.%目的 观察氨溴索、 溴己新两种方案辅治婴幼儿急性支气管炎的临床疗效. 方法 随机抽取我院于2014年9月至2015年6月期间收治的急性支气管炎患儿98例作为研究对象, 按入院顺序的不同, 分为对照组49例和观察组49例, 两组患儿均给予常规治疗, 观察组在常规治疗的基础上静脉滴注氨溴索治疗, 对照组在常规治疗的基础上静脉滴注溴己新治疗, 治疗7d后, 对比两组患儿的临床效果, 并观察两组患儿的临床症状改善时间及住院时间. 结果 观察组总有效率为97.96%, 显著高于对照组的79.59%, 差异有统计学意义 (P<0.05). 观察组咳嗽消失时间、 肺部啰音消失时间及住院时间均显著短于对照组, 差异有统计学意义 (P<0.05). 两组患儿均无不良反应发生. 结论 急性支气管炎患儿采取氨溴索治疗的临床效果显著优于溴己新, 可迅速缓解患儿的症状, 且耐受性好, 值得临床推广使用.
展开▼
